Naomi Y. Ko MD, MPH

Associate Professor, Hematology & Medical Oncology

820 Harrison Ave | (617) 638-8188
Naomi Ko
Sections

Hematology & Medical Oncology

Centers

BU-BMC Cancer Center

Center of Excellence in Women’s Health 

Evans Center for Interdisciplinary Biomedical Research

Biography

Breast Cancer
Cancer Disparities
Health Equity

Dr. Ko is an Associate Professor of Medicine at Boston University School of Medicine (BUSM) and a medical oncologist at Boston Medical Center (BMC) who has a lifelong passion for social justice. After college, Dr. Ko participated in Teach For America followed by volunteer service at the Berkeley Free Clinic in the Bay Area. She went on to Johns Hopkins School of Medicine and School of Public Health to complete her MD MPH with a focus on health outcomes research for vulnerable populations. After internal medicine residency at Brigham and Women's Hospital she arrived for fellowship in hematology/oncology at BUSM/BMC, which allowed Dr. Ko to conduct research in the context of caring for an underserved population within a large safety net institution. She has sought out meaningful projects that are a culmination of her passion for oncology, service to the underserved, and academic research. Her research has a translational focus that has been directed to understanding the disconnect between scientific discoveries in cancer treatment and delivery of evidence-based treatment to vulnerable, racial/ethnic minority women with breast cancer. She is actively investigating how tumor biology, poverty, communication and treatment influence breast cancer outcomes in diverse breast cancer populations.

Education

Medicine-Internal, MD, Johns Hopkins University School of Medicine, 2006

Epidemiology, MPH, Johns Hopkins University School of Public Health, 2005

East Asian Studies, AM, Harvard University, 2001

American Studies, BA, Barnard College, 1995

Publications

Published on 7/5/2022

Irwin KE, Ko N, Walsh EP, Decker V, Arrillaga-Romany I, Plotkin SR, Franas J, Gorton E, Moy B. Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care. Oncologist. 2022 Jul 05; 27(7):518-524. PMID: 35443045.

Published on 7/1/2022

Battaglia TA, Gunn CM, Bak SM, Flacks J, Nelson KP, Wang N, Ko NY, Morton SJ. Patient navigation to address sociolegal barriers for patients with cancer: A comparative-effectiveness study. Cancer. 2022 Jul 01; 128 Suppl 13:2623-2635. PMID: 35699610.

Published on 4/23/2022

Huang HC, Smart MH, Zolekar A, Deng H, Hubbard CC, Hoskins KF, Ko NY, Guadamuz JS, Calip GS. Impact of socioeconomic status and rurality on cancer-specific survival among women with de novo metastatic breast cancer by race/ethnicity. Breast Cancer Res Treat. 2022 Jun; 193(3):707-716. PMID: 35460499.

Published on 4/14/2022

Coleman C, Yan CH, Ko NY, Nabulsi NA, Hoskins KF, Chiu BC, Calip GS. Physical functioning, frailty and risks of locally-advanced breast cancer among older women. Breast. 2022 Aug; 64:19-28. PMID: 35468476.

Published on 2/28/2022

Calip GS, Nabulsi NA, Hubbard C, Asfaw AA, Lee I, Zhou J, Cueto J, Mitra D, Ko NY, Hoskins KF, Law EH. Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer. Cancer Causes Control. 2022 May; 33(5):793-799. PMID: 35226243.

Published on 11/19/2021

Mukand NH, Ko NY, Nabulsi NA, Hubbard CC, Chiu BC, Hoskins KF, Calip GS. The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. Breast Cancer. 2022 Mar; 29(2):287-295. PMID: 34797467.

Published on 11/12/2021

LeClair AM, Battaglia TA, Casanova NL, Haas JS, Freund KM, Moy B, Parsons SK, Ko NY, Ross J, Ohrenberger E, Mullikin KR, Lemon SC. Assessment of patient navigation programs for breast cancer patients across the city of Boston. Support Care Cancer. 2022 Mar; 30(3):2435-2443. PMID: 34767089.

Published on 8/13/2021

Zhou J, Cueto J, Ko NY, Hoskins KF, Nabulsi NA, Asfaw AA, Hubbard CC, Mitra D, Calip GS, Law EH. Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. Breast. 2021 Oct; 59:367-375. PMID: 34419726.

Published on 7/9/2021

Yan CH, Coleman C, Nabulsi NA, Chiu BC, Ko NY, Hoskins K, Calip GS. Associations between frailty and cancer-specific mortality among older women with breast cancer. Breast Cancer Res Treat. 2021 Oct; 189(3):769-779. PMID: 34241741.

Published on 7/1/2021

Zhou J, Sweiss K, Han J, Ko NY, Patel PR, Chiu BC, Calip GS. Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. JAMA Netw Open. 2021 07 01; 4(7):e2118410. PMID: 34313746.

View full list of 57 publications.